Interview with Michelle Kirschner RN, MSN, ACNP, APRN,BC: Use of the Breast Cancer Index in Guiding Extended Endocrine Therapy

Interview with Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP: Bone Health During Breast Cancer Treatment

Highlights from the 2025 ASCO Annual Meeting: Part 2

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Real-World Survival Outcomes by Risk Features in Patients with HR+, HER2− Early Breast Cancer in the US

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Abemaciclib Clinical Management Guide

Bone Health in Cancer: ESMO Clinical Practice Guidelines

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

HR+ HER2- Breast Cancer Resource Center

Interview with Michelle Kirschner RN, MSN, ACNP, APRN,BC: Use of the Breast Cancer Index in Guiding Extended Endocrine Therapy

Real-World Survival Outcomes by Risk Features in Patients with HR+, HER2− Early Breast Cancer in the US

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Abemaciclib Clinical Management Guide

Bone Health in Cancer: ESMO Clinical Practice Guidelines

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer